Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects by Coutinho, Artur M N et al.
  Universidade de São Paulo
 
2015
 
Brain metabolism and cerebrospinal fluid
biomarkers profile of non-amnestic mild
cognitive impairment in comparison to
amnestic mild cognitive impairment and
normal older subjects
 
 
Alzheimer's Research & Therapy. 2015 Sep 15;7(1):58
http://dx.doi.org/10.1186/s13195-015-0143-0
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Neurologia - FM/MNE Artigos e Materiais de Revistas Científicas - FM/MDR
RESEARCH Open Access
Brain metabolism and cerebrospinal fluid
biomarkers profile of non-amnestic mild
cognitive impairment in comparison to
amnestic mild cognitive impairment and
normal older subjects
Artur M N Coutinho1*, Fábio H G Porto2, Fabio L S Duran3, Silvana Prando1, Carla R Ono1, Esther A A F Feitosa1,
Lívia Spíndola2, Maira O. de Oliveira2, Patrícia H F do Vale2, Helio R. Gomes2, Ricardo Nitrini2,
Sonia M D Brucki2 and Carlos A. Buchpiguel1
Abstract
Introduction: Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and
dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory
decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosis as compared to amnestic
subtypes of MCI (aMCI). Unfortunately, studies investigating biomarker profiles of naMCI are scarce. The study objective
was to investigate the regional brain glucose metabolism (rBGM) with [18F]FDG-PET and cerebrospinal fluid (CSF)
biomarkers in subjects with naMCI as compared to a control group (CG) and aMCI subjects.
Methods: Ninety-five patients were included in three different groups: naMCI (N = 32), aMCI (N = 33) and CG (N = 30).
Patients underwent brain MRI and [18F]FDG-PET. A subsample (naMCI = 26, aMCI = 28) also had an assessment of
amyloid-β, tau, and phosphorylated tau levels in the CSF.
Results: Both MCI groups had lower rBGM in relation to the CG in the precuneus. Subjects with naMCI showed
decreased right prefrontal metabolism as well as higher levels of CSF amyloid-β relative to aMCI subjects.
Conclusion: While amnestic MCI subjects showed a biomarker profile classically related to MCI due to Alzheimer’s
disease, naMCI patients illustrated a decrease in both prefrontal hypometabolism and higher CSF amyloid-β levels
relative to the aMCI group. These biomarker findings indicate that naMCI is probably a heterogeneous group with
similar precuneus hypometabolism compared to aMCI, but additional frontal hypometabolism and less amyloid-β
deposition in the brain. Clinical follow-up and reappraisal of biomarkers of the naMCI group is needed to determine
the outcome and probable etiological diagnosis.
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Introduction
Mild cognitive impairment (MCI) is assumed to be a
transitional stage between normal aging and dementia.
Clinically, MCI has several etiologies and includes two
main subtypes, amnestic MCI (aMCI) and nonamnestic
MCI (naMCI) [1]. aMCI forms are typically considered a
symptomatic predementia phase of Alzheimer’s disease
(AD), while naMCI forms are believed to be more re-
lated to other neurodegenerative or nondegenerative
conditions, such as vascular or psychiatric disorders [1].
Thus, while the heralding impairment of aMCI is char-
acteristically a memory deficit, the naMCI subtype typic-
ally shows a greater preservation of memory function
with larger degrees of deficits in the cognitive domains
such as attention, language, visuospatial, and executive
functions [2, 3]. Previous research has shown that in
most cohorts [4, 5], but not all [6], naMCI presented a
lower rate of conversion to dementia than the amnestic
subtype. Most studies indicate a preferential conversion
of aMCI to AD, but other variables such as the presence
of more than one affected domain, type of impairment,
intensity of cognitive impairment at baseline, and pres-
ence of apolipoprotein E epsilon 4 allele may possibly
influence the conversion to dementia [7].
According to the most currently accepted theory of
AD physiopathology [8], if naMCI is due to disorders
other than AD, then biomarkers should be different in
aMCI and naMCI. Some authors have compared mag-
netic resonance imaging (MRI) and positron emission
tomography with 18F-fluordeoxyglucose ([18F]FDG-PET)
in both MCI subtypes, concluding that aMCI shows im-
aging patterns more consistent with a transition to AD,
like hypometabolism in the posterior cingulate and tem-
poroparietal regions [8], than naMCI [9–12]. However,
most studies have not identified a distinct set of imaging
and cerebrospinal fluid (CSF) biomarkers necessary to
specifically characterize naMCI, thereby leaving ambigu-
ity in which parameters might best classify nonamnestic
forms of MCI.
Given these outstanding issues, the aim of the present
study was to compare the profiles of naMCI, aMCI, and
control older subjects with [18F]FDG-PET (a surrogate
marker of synaptic function) and CSF biomarkers (a meas-
urement of brain amyloid deposition and neuronal injury),
in efforts to not only illustrate the relationship between
naMCI and aMCI CSF biomarkers, but also demonstrate
synaptic functioning differences between the groups.
Materials and methods
Participants
Community-dwelling older adults (≥60 years old) were
recruited through community announcements and in-
vited to participate in meetings hosted in recreation cen-
ters throughout the city of São Paulo, Brazil. Subjects
reporting any cognitive complaints were evaluated by a
neurologist (FHGP). Cognitive complaints needed to be
reported by the subjects and were confirmed by a collat-
eral source, usually a relative or spouse. To be included
in the study, subjects had to have completed 4 years or
more of formal education, or what constitutes “primary
education” in Brazil. Older volunteers without cognitive
complaints were also recruited as members of the con-
trol group (CG). All participants underwent a complete
neurological and psychiatric evaluation, a comprehensive
neuropsychological test battery, and an assessment for
symptoms of depression and anxiety. After each initial
assessment, a final diagnosis was established by a con-
sensus of neurologists with expertise in cognitive and
behavioral neurology.
The revised Petersen et al. [13] criteria were used to
diagnose individuals with MCI. Classification of aMCI or
naMCI was determined according to the presence or ab-
sence of impairment in memory tasks (which defines
aMCI), or other cognitive domains in the neuropsycho-
logical assessment [3, 13]. We considered a cognitive
function or domain to be impaired if the test Z scores
on that function were greater than 1.5 below the appro-
priate mean for age and education on one test, or if the
Z scores were between 1.0 and 1.5 below the appropriate
mean on more than one test of the same cognitive do-
main [14]. MCI patients were classified into aMCI or
naMCI according to the criteria described. The domains
impaired in the naMCI group were: executive/attention
(n = 25), executive/attention and language (n = 5), and
executive/attention and visuospatial function (n = 2).
The cognitive battery used to screen subjects included
the Mini-Mental State Examination (MMSE) [15, 16] and
the Brief Cognitive Battery [17] followed by the clock
drawing test [18]. This battery has been shown to have
good accuracy for the diagnoses of early dementia [19].
The following neuropsychological tests were used to define
naMCI and aMCI: memory tests (visual reproduction and
logical memory subtests of the Wechsler Memory Scale
(revised), delayed recall of the Rey–Osterrieth Complex
Figure, and the Rey Auditory Verbal Learning Test); con-
structive abilities (Block Design subtest of the Wechsler
Adult Intelligence Scale, and copy of the Rey–Osterrieth
Complex Figure); visual perception (matrix reasoning); and
attention and executive functions (Trail Making Test (Parts
A and B) and the Stroop Test). Application, scoring, and
interpretation of the results obtained for all tests were per-
formed according to each reference guide. Scores were ad-
justed according to appropriate age and education norms.
Additional details of the evaluation protocol used, and
neuropsychological tests administered, are reported in de
Gobbi Porto et al. [20].
Exclusion criteria included: volunteers with clinically rele-
vant psychiatric symptoms meeting DSM-IV criteria (the
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Geriatric Depression Scale (GDS) [21] and the Geriatric
Anxiety Inventory [22] were administered to all MCI pa-
tients to evaluate the intensity of depressive and anxiety
symptoms, respectively; patients with scores >5 on the
GDS were excluded); any uncompensated clinical comor-
bidity, such as cardiac failure or anemia; history or presence
of signs of neurologic diseases, such as Parkinson’s disease,
epilepsy, inflammatory disease or stroke, with the exception
of migraine; presence of any drug abuse (especially alcohol-
ism); cognitive decline intense enough to interfere with
daily activities according to clinical judgment or a score of
≥5 on the Functional Activities Questionnaire [23]; cogni-
tive decline consistent with a diagnostic of dementia ac-
cording to clinical judgment; diabetes mellitus without
adequate glycemic control in the last 2 weeks (excluded be-
cause of possible interference with the [18F]FDG-PET); and
presence of neoplastic or significant vascular lesions on the
MRI scan, according to the judgment of a neuroradiologist
(EAAFF) and one of the authors (AMNC). Individuals were
not excluded based on the presence of white matter hyper-
intensities (WMH) on the MRI scan. The presence of
WMH was an exclusionary criterion only if associated with
focal neurological signs or gait impairment in the neuro-
logic examination. No patient was using cholinesterase in-
hibitors or memantine. Antidepressant use was not strictly
exclusionary; patients using antidepressants were allowed
to participate if they were on a stable dose for at least 3
months and did not have symptoms of an active psychiatric
disease at the time of screening.
This research project was approved by the ethics com-
mittee of the Hospital das Clínicas da Faculdade de
Medicina da Universidade de São Paulo, and was in
agreement with the provisions of the Declaration of
Helsinki. All participants signed a term of consent.
CSF analysis
Of the 65 MCI patients enrolled, 54 (aMCI, 28 patients;
naMCI, 26 patients) agreed to have a lumbar puncture
to assess amyloid beta peptide (Aβ), tau, and phosphory-
lated tau (p-tau) protein levels in the CSF. Lumbar
punctures were performed after an 8-hour fast, always
between 8:00 and 10:00 a.m. A 22-gauge spinal needle
was inserted between the fourth or fifth lumbar verte-
bral body by a trained neurologist. Approximately 10 ml
CSF were taken. All of the samples were collected in
polypropylene tubes, briefly centrifuged, and stored at a
temperature of −80 °C. Total tau, p-tau, and Aβ were
determined quantitatively using a commercial sandwich
enzyme-linked immunosorbent assay (Innotest hTAUAg
Innotest _amyloid 1–42; Innogenetics, Ghent, Belgium).
MRI acquisition
After the initial work-up, all patients underwent a 3.0
Tesla MRI scan to exclude structural diseases and also
for co-registration with [18F]FDG-PET images. Following
the procedure outlined in Fazekas et al. [24], a neurora-
diologist (EAAFF) performed a visual semi-quantitative
assessment of a WMH scale, using the axial fluid-attenu-
ated inversion recovery (FLAIR) sequence. The following
MRI sequences were acquired: sagittal 3D T1, axial T2
FSE, axial fluid-attenuated inversion recovery (FLAIR),
coronal T2 SPIR, and diffusion.
[18F]FDG-PET imaging acquisition
To ensure blood glucose levels lower than 180 mg/ml,
participants fasted for at least 4 hours prior to the intra-
venous injection of 370 MBq [18F]FDG in a peripheral
vein. Following the tracer injection, patients rested with
eyes open and ears unplugged for 60 minutes in a calm,
silent and slightly darkened room. Acquisition of the
[18F]FDG-PET data was run for 15 minutes (matrix =
256 × 256, zoom = 2.5, pixel size = 1.04 mm) using a
Siemens Biograph PET-CT scanner (CTI/Siemens,
Knoxville, TN, USA). Images were reconstructed with
the ordered subset expectation maximization method
(with six interactions and 16 subsets) and then
smoothed with a 5 mm Gaussian filter. Data were also
corrected for scattering, attenuation, and decay. Attenu-
ation correction was performed using single helical com-
puted tomography.
[18F]FDG-PET imaging processing and analysis with SPM8
The following procedures were validated previously [25]
and are used as a standard for PET and single photon
emission tomography (SPECT) explorative analyses. All
PET images of the participants were co-registered with
the their MRI images (volumetric T1 sequence) and
spatially normalized in SPM8 software (Wellcome De-
partment of Cognitive Neurology, Functional Imaging
Laboratory, London, UK) into a standard stereotactic
space, based on the SPM8/Montreal Neurologic Institute
space, using a 12-parameter linear affine normalization
and a further nonlinear iteration algorithm. This was
performed using an SPM8 template for [18F]FDG-PET.
Each of the scans was also individually smoothed with a
Gaussian kernel to reduce the impact of misregistration
into template space and to improve the signal-to-noise ra-
tio. Images were then smoothed with a 4 mm full-width
Gaussian kernel at half-maximum Gaussian filter. To en-
sure the analysis only included voxels mapping cerebral tis-
sue, a default threshold of 0.8 of the mean uptake inside the
brain was selected. Global uptake differences between brain
scans were adjusted using the “proportional scaling” statis-
tical parametric mapping (SPM) option. Once adjusted,
radioactive counts for each participant were normalized
with the average global counts of each group (i.e., the
“global means” normalization approach). The relevant
peak voxels were identified in terms of coordinates
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according to Talairach and Tournoux with the help of
the Talairach Client software (Research Imaging Insti-
tute, University of Texas Health Science Center, San
Antonio, TX, USA), and after conversion from the
SPM/Montreal Neurological Institute space [26, 27].
Statistical analysis
Clinical and CSF data analyses were performed using
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). PET
data were analyzed on a voxel-by-voxel basis using the
SPM8 software (Wellcome Department of Cognitive
Neurology) in conjunction with MATLAB R2009a (The
Mathworks In., Natick, MA, USA). An analysis of variance
(ANOVA) test was used to search for regional brain glu-
cose metabolism (rBGM) differences across the three
groups (naMCI, aMCI, and CG).
Post-hoc analyses with nonpaired t tests were used to
examine differences between each pair of groups. SPM8
maps were generated with p <0.001 and the threshold
for significance at the voxel level was set at p = 0.001
(Z score = 3.09) with a minimum extension of 10 voxels
in the corresponding cluster. This is a classical thresh-
old for PET and functional MRI studies [25], and has been
used previously in studies related to MCI [9, 11, 28].
The initial exploratory analyses with SPM maps gen-
erated a t statistic for each voxel, thus constituting
statistical parametric maps.
To explore the homogeneity of rBGM alterations be-
tween groups in particular areas, the higher Z scores
within each map were identified, and a volumetric region
of interest (ROI) in the corresponding cluster of voxels
was generated. Subsequently, numeric values represent-
ing [18F]FDG uptake measures in that cluster for each
individual (after the whole normalization process) were
obtained with the toolbox MarsBar for SPM [29] under
the option “explore design/files and factors”. With this
approach, regions of particular interest—voxels in the
precuneus—could be better explored.
A directed analysis of ROIs was also completed with
the SPM8 software (small volume correction (SVC)).
Areas in the temporoparietal association cortex were
chosen based on previous reports of regions with typical
metabolic impairment in early AD [30, 31]. The following
areas were analyzed: posterior cingulate cortex, precuneus,
angular gyrus, middle temporal gyrus, and inferior
temporal gyrus.
Results
Ninety-five volunteers were included and classified into
one of three groups: aMCI group (aMCI; n = 33), naMCI
group (naMCI; n = 32), or without cognitive impairment
group (CG; n = 30). Demographic, clinical, and CSF data
are presented in Table 1. The CG had more years of for-
mal education than aMCI patients (mean (M) and
standard deviation (SD) of 12.9 (4.9) and 9.2 (4.0), re-
spectively; p = 0.017). The MMSE was different between
the CG and both MCI groups (M (SD) = 29.0 (1.0), 27.6
(1.5), and 27.8 (1.9) for CG, aMCI, and naMCI, respect-
ively; p <0.000). No differences were found in age, gen-
der, education, intensity of depressive or anxiety
symptoms, presence of hypertension and diabetes, or
MMSE scores among the aMCI and naMCI groups. Vis-
ual analysis of WMH [24] disclosed no differences across
the groups.
In the subsample with available lumbar puncture (n =
54; aMCI, 28 patients; naMCI, 26 patients), CSF bio-
marker analysis depicted lower concentrations of CSF
Aβ peptide in aMCI in relation to naMCI (M (SD) = 704
(248) and 918 (430), respectively; p = 0.04). No differ-
ences were found in tau, p-tau, and p-tau/Aβ protein ra-
tio measures. To facilitate the visualization of the
dispersion of CSF biomarkers values among aMCI and
naMCI patients, Fig. 1a shows box-plot graphics of the
Z scores (two groups combined) for CSF Aβ, tau, p-tau,
and CSF Aβ/p-tau ratio.
Complete SPM8 data are presented in Table 2 and com-
prise the region of rBGM alterations in the ANOVA test
and rBGM reductions in the post-hoc analysis, as well as
its extension (number of voxels) and level of statistical sig-
nificance. When compared with CG, naMCI exhibited sta-
tistically significant [18F]FDG-PET rBGM reductions in
the following Broadmann areas (BAs): right middle frontal
gyrus (BA8 and BA9, p <0.001; and BA10, p = 0.001), right
inferior frontal gyrus (BA9, p <0.001), two contiguous
areas in the precuneus (BA7, p = 0.001), and another area
in the left superior occipital gyrus (BA19, p <0.001). The
naMCI group exhibited reduced rBGM in right middle
frontal gyrus (BA46, p <0.001) in relation to aMCI.
The aMCI group showed decreased rBGM in relation to
CG in the left precuneus (BA7 and BA31, p <0.001) and in
the left middle temporal gyrus (BA39, p <0.001). When
compared with naMCI, aMCI showed reduced rBGM in
the left temporal lobe (p <0.001). Figure 2 shows an illus-
trative anatomic localization of the peak voxels of rBGM
reductions as measured with [18F]-FDG-PET.
Results from the ANOVA indicated a significantly lar-
ger number of years of education for the control group
relative to aMCI subjects (p = 0.01, CG >aMCI). The
ANOVA also showed a statistical tendency for the CG
to be slightly older than aMCI subjects (p = 0.06). Be-
cause these variables—especially education—could pos-
sibly influence the metabolic pattern in prodromal AD
[32, 33], an analysis controlling for age and education
was conducted; the results were not significantly chan-
ged after controlling for age and education.
SVC analysis of the temporoparietal association cortex
of the aMCI and naMCI groups against the CG disclosed
significant areas of rBGM reduction, after correction for
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multiple comparisons (family-wise error correction
method (FWE)), in the left precuneus (BA31) in the
aMCI group (pFWE = 0.025) and in two contiguous areas
in the left angular gyrus (BA39) in the naMCI group
(pFWE = 0.033 and 0.040).
The authors also designed ROIs to extract mean radio-
active counts of the areas with statistically significant
rBGM reduction in the precuneus of the three groups
(as detailed in Materials and methods). Box-plot graph-
ics were also generated in efforts to investigate the pos-
sible heterogeneity of neurodegeneration in these areas
across all subjects. The results are shown in Fig. 1b.
Discussion
Our results showed that naMCI patients presented a re-
duction of rBGM in the right prefrontal cortex relative
to control patients, and in the right middle frontal gyrus
relative to aMCI patients. Both MCI groups presented
decreased rBGM with similar localization of decline, in
the precuneus, in relation to the CG. Additionally, the
aMCI group had significantly lower levels of CSF Aβ
peptide, indicating increased deposition in the brain, and
decreased left temporal lobe metabolism relative to the
naMCI group.
Reduction of rBGM in the precuneus was seen in both
the aMCI and naMCI groups relative to the CG. This
area is believed to be an important component of the
default mode network, a network that is structurally and
functionally affected in normal aging and more promin-
ently, and very early, in AD [34–36]. The precuneus and
posterior cingulate cortex seem to be particularly vulner-
able to Aβ deposition and metabolic dysfunction [36, 37].
Lower rBGM and cerebral blood flow in this region are
commonly associated with a faster rate of progression
from MCI to AD [28, 30, 31, 38].
These results indicate that both the aMCI and naMCI
groups have significant rBGM reductions in the postero-
medial parietal cortex relative to the CG. These data are
in line with Clerici et al. [9], who found that subjects
with single-domain aMCI and naMCI have significant
Table 1 Demographic, neuropsychological, and CSF data for the sample
CG (n = 30) aMCI (n = 33) naMCI (n = 32) p value (two-tailed)
Multiple comparison
Age (years)a 69.5 (6.4) 72.6 (5.5) 69.8 (5.8) 0.065
Gender (female/male)b 24/6 20/13 23/9 0.23
Education (years)a 12.9 (4.9) 9.2 (4.0) 11.8 (4.3) 0.018
CG × aMCI
(p = 0.017)
GDSc – 1.5 (1.3) 1 (1.4) 0.113
GAIc – 6.6 (4.3) 5.1 (4.1) 0.181
Hypertensionb – 19 (57 %) 15 (46 %) 0.388
Diabetes mellitusb – 7 (21 %) 3 (9 %) 0.186
MMSEa 29.0 (1.0) 27.6 (1.5) 27.8 (1.9) 0.000
CG × aMCI and naMCI
(p <0.003)
CSF Aβc,d – 704 (248) 918 (430) 0.044
CSF tauc,d – 258 (125) 247 (110) 0.84
CSF p-tauc,d – 44 (12) 43 (14) 0.97
CSF p-tau/Aβ proteind 0.07 (0.05) 0.06 (0.04) 0.13
WMH visual scaleb [24] 0: 06 (20 %) 0: 04 (12 %) 0: 04 (13 %) 0.525
I: 13 (43 %) I: 16 (49 %) I: 18 (56 %)
II: 08 (27 %) II: 09 (27 %) II: 10 (31 %)
III: 03 (10 %) III: 04 (12 %) III: 0 (0 %)
Data presented as mean (standard deviation)
aAnalysis of variance (post-hoc test: Bonferroni)
bChi-square test
ct test
dSubsample of 54 subjects (26 naMCI patients and 28 aMCI patients), Mann–Whitney test (not normally distributed)
aMCI amnestic mild cognitive impairment, Aβ amyloid beta, CG control group, CSF cerebrospinal fluid, GAI Geriatric Anxiety Scale, GDS Geriatric Depression Scale
(15 items), MMSE Mini-Mental State Examination, naMCI nonamnestic mild cognitive impairment, p-tau phosphorylated-tau, WMH white matter hyperintensities
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medial parietal cortex (posterior cingulate cortex) hypo-
metabolism in relation to normal older subjects. The au-
thors also reported additional metabolic reductions in
the medial temporal lobe of aMCI in relation to naMCI,
which was not replicated in the results outlined in the
present article. However, our results do indicate that
aMCI subjects still had a reduction of rBGM in the left
temporal lobe in comparison to naMCI (Table 2).
Our findings—that there is an rBGM reduction in the
right prefrontal areas in the naMCI group in relation to
Table 2 rBGM comparison between aMCI, naMCI, and CG using SPM8a. Results showing areas of rBGM reduction
Z score p value Cluster size (number of voxels) Peak voxel coordinates (Talairach)
aMCI × CGb
Left middle temporal gyrus, BA39 3.51 <0.001 41 −46 −67 20
Left precuneus, BA31 3.17 <0.001 33 −4 −51 32
Left precuneus, BA7 3.33 <0.001 15 −2 −63 64
aMCI × naMCIb
Left temporal lobe 3.62 <0.001 167 −44 −45 2
naMCI × control groupb
Right inferior frontal gyrus, BA9 3.80 <0.001 34 46 11 29
Right middle frontal gyrus, BA9 3.40 <0.001 51 34 34 28
Right middle frontal gyrus, BA8 3.32 <0.001 51 32 29 39
Right middle gyrus, BA10 3.24 0.001 11 38 45 16
Left superior occipital gyrus, BA19 3.42 <0.001 41 −42 −72 28
Left precuneus, BA7 3.20 0.001 32 0 −63 60
Left parietal lobe, BA7 3.16 0.001 32 −4 −62 70
naMCI × aMCIb
Right middle frontal gyrus, BA46 3.33 <0.001 19 51 29 26
aResults at the peak voxel level (global analysis, analysis of variance and post-hoc nonpaired t test). SPM8 software from Wellcome Department of Cognitive Neurology
(Functional Imaging Laboratory, London, UK)
bUncorrected for multiple comparisons
aMCI amnestic mild cognitive impairment, BA Broadmann area, CG control group, naMCI nonamnestic mild cognitive impairment, rBGM regional brain glucose metabolism
Fig. 1 Box-plot graphics for CSF biomarkers and mean radioactive counts. a Z scores for CSF Aβ, tau, p-tau, and p-tau/Aβ ratio proteins in each
group. b Mean radioactive counts in the three areas of the precuneus which presented rBGM differences between aMCI and CG (PREC_area 1
and 2) and naMCI and CG (PREC_area 3). •1.5 times the interquartile range, *more than 1.5 times the interquartile range; +value is actually 5.1 SD
(outlier). aMCI amnestic mild cognitive impairment, CG control group, naMCI nonamnestic mild cognitive impairment, p-tau phosphorylated tau
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the CG, and to a lesser extent in relation to the aMCI
group—suggest there is some relation with an rBGM re-
duction in the right prefrontal areas and the impair-
ments of executive function and attention, but not
memory deficits, presented by naMCI patients. The dorso-
lateral prefrontal cortex is classically associated with ex-
ecutive functions and has strong anatomic and functional
connections to attentional and executive brain networks
[39, 40]. These findings are in agreement with previous
studies that revealed blood flow and volumetric reductions
in frontal lobes of patients with naMCI [10, 11].
A volumetric reduction in the left dorsolateral pre-
frontal cortex was shown in single-domain dysexecutive
MCI relative to the control group [11]. Nobili et al. [10]
reported blood flow reductions in the right frontal cor-
tex of naMCI patients as compared with patients with
subjective memory complaints. However, methodological
differences such as a high rate of depression and WMH
in the naMCI group, use of SPECT instead of PET, and
the analysis of preselected ROIs disallow an easy compari-
son between the results presented in the present study
and those published previously. In the former study [10],
vascular disease or depression may have accounted in part
for the frontal hypoperfusion. Small white matter and sub-
cortical vascular lesions correlate negatively with dorsolat-
eral prefrontal cortex activity, and thus could be responsible
for executive and attentional dysfunctions [41, 42]. As
described, any subjects with clinically diagnosed depres-
sion, depression that restricted normal daily activity, or
cerebral infarcts were excluded. Notably, we found no
differences in cerebrovascular risk factors and WMH
intensity on MRI across the groups. Thus, even though
MRI may miss cortical microinfarcts in some cases, vascu-
lar disease is unlikely to be the main cause of the frontal
hypometabolism in the naMCI group [43].
aMCI subjects had lower levels of Aβ peptide as com-
pared with the naMCI subjects (Table 1). A meta-analysis
of the relationship between brain amyloid biomarkers in
normal older adults suggested a closer relationship be-
tween brain amyloid with memory function than with
other cognitive functions [44]. A similar correlation has
been shown in aMCI but not naMCI patients [45]. The
fact that lower Aβ levels in the CSF are thus linked to a
greater deposition of amyloid plaques in the brain possibly
indicates that the aMCI subgroup is more similar to a
pathological state of AD than the naMCI group [46, 47].
This relationship further suggests that aMCI patients are
more likely than naMCI patients to be diagnosed with AD
in the future [48]. In line with our finding, lower cortical
Aβ deposition measured with [11C]PIB-PET was also
found in naMCI in comparison with aMCI [49].
There was no difference in tau and p-tau proteins
levels between the aMCI and naMCI groups. The tau
and p-tau proteins are associated with neurofibrillary
tangles, which are more associated with synaptic dys-
function, brain atrophy, and cognitive and functional im-
pairment than Aβ [8, 46, 47]. Together with brain
atrophy and [18F]FDG-PET hypometabolism, tau and p-
tau are classified as biomarkers of neural injury or de-
generation [8]. The CSF tau and p-tau results are in par-
tial agreement with the [18F]FDG-PET findings, showing
similar precuneus hypometabolism in both MCI groups,
thereby potentially indicating that the two MCI groups
are not in different stages of neural degeneration. Inter-
estingly, a recent study found cognitively normal sub-
jects with positive biomarkers of neurodegeneration and
no Aβ accumulation [50]. Those same subjects, however,
later developed Aβ deposits [50], indicating that the tra-
jectories of Aβ accumulation and injury biomarkers may
be independent from one another [51]. These findings
may help explain the results in the biomarker profile of
the present study’s naMCI group, which showed similar
neuronal injury biomarkers in both MCI groups but less
brain Aβ deposition in naMCI patients.
The additional frontal hypometabolism in naMCI,
however, remains an open question. Cerami et al. [52]
recently reported a follow-up cohort study of MCI
accessed with [18F]FDG-PET at diagnosis, including
eight naMCI patients. In Cerami et al.’s study, two pa-
tients with naMCI and frontal hypometabolism later de-
veloped frontotemporal lobar degeneration (FTLD),
implying that FTLD remains a possible explanation for
the development of frontal hypometabolism in naMCI
patients. The authors of the current study believe this
explanation to be unlikely, however, primarily because
Fig. 2 Illustrative anatomic localization of the peak voxels of rBGM
reductions as measured with [18F]-FDG-PET. a1, a2 naMCI rBGM
reductions in relation to the CG, predominantly in right prefrontal
areas but also in the precuneus and a left prefrontal area without
statistic significance; a3 naMCI rBGM reductions in relation to the
aMCI group (right prefrontal area). b1, b2 Bilateral metabolic
reduction in the precuneus, parietal, and temporal cortex is seen in
the aMCI group in comparison with normal older subjects; b3
hypometabolism is also noted in the left temporal lobe in aMCI in
relation to naMCI
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none of our participants presented with behavioral
changes, which are a major clinical feature in FTLD and
were an exclusionary criterion in our study.
Executive dysfunction and impaired attention are both
unspecific findings that are related to the prefrontal cortex
[39, 40, 53], and may be present in several etiologies with-
out concomitant neurodegeneration, such as in psychiatric
diseases [53]. The hypometabolism seen in the naMCI
group may therefore be due to a “functional network
dysregulation” of the attentional and executive networks,
although with still unknown origin.
Clinical follow-up and reappraisal of biomarkers for the
naMCI group is crucial in determining the outcome and
probable etiological diagnosis of naMCI patients. The
naMCI group could be composed of patients with different
etiological entities, such as aging-associated executive and
processing speed dysfunctions [37], prodromic presentation
of non-AD neurodegenerative diseases [52], atypical pre-
sentations of AD (e.g., frontal executive AD) [54], nonde-
generative cognitive impairment (e.g., vascular disease), and
even preamnestic forms of MCI owing to AD. Follow-up is
fundamental in drawing any conclusions about this issue.
Taking into account the possibility of non-Aβ degeneration
[50, 51] and the fact that executive function is an unspecific
finding, naMCI is probably a different type of degeneration
than aMCI, not necessarily a milder one. This distinction
can only be clarified with a long-term follow-up.
Our study has some limitations. First, because
naMCI probably represents a heterogeneous group,
additional studies with larger patient samples are
needed. Second, additional investigations of naMCI
samples should be performed using other imaging
biomarkers modalities, such as volumetric analysis
with MRI, and other variables, such as genetic ana-
lysis, measures of cognitive reserve, lifestyle, and so
forth. Third, [18F]FDG-PET imaging was acquired in
the resting state. For that reason, discussions relating
rBGM to neuropsychological functions (i.e., frontal
hypometabolism and executive function) should be
considered only speculative; more investigation is war-
ranted before these observations can be confirmed.
Finally, our patient population was a convenience
sample from the community; future studies would
benefit from incorporating a variety of different popu-
lations (e.g., subjects from a tertiary memory clinic).
Conclusions
The naMCI and aMCI groups presented some similarities
in their biomarker profile. Both groups presented the
same levels of tau and p-tau proteins in the CSF and a re-
duction of rBGM in parietal areas (mainly the precuneus)
relative to controls. However, some important differences
were noted between the two groups: aMCI patients had
lower levels of Aβ peptide in the CSF and left temporal
hypometabolism and increased right prefrontal cortex
rBGM relative to naMCI patients. Ultimately, these results
illustrate that aMCI patients had a biomarker profile more
similar to MCI owing to AD, while naMCI patients illus-
trate a different—and varied—pattern of degeneration.
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